The place of combined hormonal contraceptives in the therapy for acne in women

Cover Page

Cite item

Full Text

Abstract

Hyperandrogenism plays a very important role in the pathogenesis of acne. Androgens contribute to sebaceous gland hyperplasia, increased sebum production and hyperkeratosis. Excessive effects of androgens on the skin are caused by hyperandrogenism associated with various endocrine syndromes or an increased sensitivity of skin receptors to normal concentrations of male sex hormones and local hyperproduction of androgens. The use of combined oral contraceptives (COCs) has therapeutic potential in the treatment of acne in patients with hyperandrogenism and in women with normal androgen levels. The use of COCs can be an alternative to systemic therapy with antibacterial drugs and retinoids. The decision on the administration of COCs to patients with acne should be made together by a dermatologist, gynecologist or endocrinologist.

About the authors

Yulia B. Uspenskaya

Medical Center NEBOLIT

Email: jusp@mail.ru
д-р мед. наук Moscow, Russia

References

  1. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008; 27: 188-96.
  2. Горячкина М.В. Роль психоэмоциональных факторов в развитии акне. Дерматология (Прил. к журн. Consilium Medicum). 2008; 2: 8-12.
  3. Горячкина М.В. Комбинированная терапия акне у женщин: поиск оптимальных решений. Вестн. дерматологии и венерологии. 2014; 2: 90-5.
  4. O'Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome 2018; 6 (1): 177. doi: 10.1186/s40168-018-0558-5
  5. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (Suppl. 1): S1-S37. doi: 10.1067/mjd.2003.618
  6. Горячкина М.В., Белоусова Т.А. Современные представления о патогенезе, клинике и терапии акне у женщин. Рус. мед. журн. 2012; 22: 1153-8.
  7. Доброхотова Ю.Э., Джобава Э.М., Рагимова З.Ю. и др. Синдром гиперандрогении в практике акушера-гинеколога, дерматолога, эндокринолога: руководство для врачей. М. : ГЭОТАР-Медиа, 2009.
  8. Bansal P, Sardana K, Sharma L et al. A prospective study examining isolated acne and acne with hyperandrogenic signs in adult females. J Dermatolog Treat 2020; 1-4. doi: 10.1080/09546634.2019.1708245
  9. Zaenglein A, Pathy A, Schlosser B et al. Guidelines of care for the treatment of acne vulgaris. J Am Acad Dermatol 2016; 74 (5): 945-73.
  10. Choudhry R, Hodgins MB, Van der Kwast TH et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992; 133 (3): 467-75. doi: 10.1677/joe.0.1330467
  11. Thiboutot DM, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997; 136 (2): 166-71
  12. Arrington E, Patel N, Gerancher K et al. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis 2012; 90 (2): 83-90.
  13. Kurokawa I, Danby F, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18: 821-32.
  14. Arowojolu O, Gallo M, Lopez L et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 6: CD004425.
  15. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first lineb therapy? facts and controversies. Clin Dermatol 2010; 28 (1): 17-23.
  16. Lucky A, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebocont-rolled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82: 143-50.
  17. Marson JW, Baldwin HE. An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin. Dermatol Clin 2019; 37 (2): 195-203. doi: 10.1016/j.det.2018.12.002
  18. Акне. Клинические рекомендации. 2016. Рубрикатор клинических рекомендаций Минздрава РФ. http://cr.rosminzdrav.ru/schema.html?id=721#/text
  19. Oon HH, Wong SN, Aw DCW et al. Acne Management Guidelines by the Dermatological Society of Singapore. J Clin Aesthet Dermatol 2019; 12 (7): 34-50.
  20. Bhate K, Williams HC. What’s new in acne? An analysis of systematic reviews published in 2011-2012. Clin Exp Dermatol 2014; 39 (3): 273-8.
  21. Koltun W, Lucky A, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249-56.
  22. Maloney J, Dietze P, Watson D et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009; 8: 837-44.
  23. Maloney J, Dietze P Watson D et al. Treatment of acne using a 3-milligram drospirenone/20- microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112: 773-81.
  24. Plewig G, Cunliffe W, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80: 25-33.
  25. Nast A, Dreno B, Bettoli V et al. European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version. J Eur Acad Dermatol Venereol 2016; 30 (8): 1261-8. doi: 10.1111/jdv.13776
  26. Rich P. Hormonal contraceptives for acne management. Cutis 2008; 81 (Suppl. 1): 13-8.
  27. Zouboulis CC, Rabe T Hormonal antiandrogens in acne treatment. J Dtsch Dermatol Ges 2010; 1 (Suppl. 8): S60-S74.
  28. Koltun W, Maloney J, Marr J et al. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155: 171-5.
  29. Beral V, Hermon C, Kay C et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners: oral contraception study. BMJ 1999; 318: 96-100.
  30. Kim G, Michaels B. Post-adolescent acne in women: more common and more clinical considerations. J Drugs Dermatol 2012; 11: 708-13.
  31. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol 2012; 24: 235-40.
  32. Lidegaard O, Edstrom B, Keriner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187-96.
  33. Lam C, Zaenglein A. Contraceptive use in acne. Clin Dermatol 2014; 32 (4): 502-15.
  34. Drife J. The contraceptive pill and breast cancer in young women. BMJ 1989; 298: 1269-70.
  35. Sasieni P Cervical cancer prevention and hormonal contraception. Lancet 2007; 370: 1591-2.
  36. Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol 2018; 218 (1): 88-97.e14. doi: 10.1016/j.ajog.2017.07.003
  37. Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 1999; 59 (2): 71-8. doi: 10.1016/s0010-7824(99)00009-8

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies